Missouri Attorney General Files Lawsuit Against EDP Kratom, Raising Stakes for Industry Compliance

Missouri Attorney General Files Lawsuit Against EDP Kratom, Raising Stakes for Industry Compliance

JEFFERSON CITY, MO – The Missouri Attorney General Catherine Hanaway has filed a lawsuit against Relax Relief Rejuvenate Trading LLC, operating as EDP Kratom, alleging unlawful manufacturing, distribution, and sale of kratom and its alkaloids, including 7-hydroxymitragynine (7-OH) and dihydro-7-hydroxymitragynine (MGM-15). This legal action marks a significant development in the ongoing scrutiny of the kratom industry and carries crucial implications for merchants and consumers nationwide.

What Happened: The lawsuit, filed in the Circuit Court of Cole County, accuses EDP Kratom of marketing its products without the necessary safety testing and regulatory approvals mandated by state and federal law. Furthermore, the Attorney General's petition alleges that EDP Kratom failed to adequately disclose dangerous active ingredients, downplayed the risks of addiction and withdrawal, and omitted any mention of overdose risks associated with its products. Disturbingly, the company is also accused of shipping free 7-OH products to consumers known to struggle with addiction, effectively perpetuating a cycle of substance dependence.

This action follows a June 2025 FDA warning letter to EDP Kratom regarding 7-OH and a subsequent investigation launched by the Missouri Attorney General's office in November 2025. The U.S. Justice Department also seized thousands of 7-OH products from EDP Kratom's warehouses. The Attorney General is seeking a court declaration that EDP Kratom's practices violate the Missouri Merchandising Practices Act, an injunction against further advertising or sale of kratom and 7-OH products, and a $1,000 penalty per violation. This is the second lawsuit to emerge from 22 ongoing investigations into kratom products by the Missouri Attorney General's office.

Why It Matters to Kratom Merchants and Consumers: For consumers, this lawsuit underscores the critical importance of product transparency and safety within the kratom market. The allegations highlight the potential dangers of unregulated products that may contain undisclosed or highly concentrated psychoactive compounds like 7-OH, which the Attorney General has labeled a "hazardous opioid." Consumers are reminded that they have a right to accurate information about the substances they consume, including potential risks of addiction, withdrawal, and overdose.

For kratom merchants, this case serves as a stark warning regarding the legal and reputational risks of non-compliance. It demonstrates an aggressive stance by state regulators against companies perceived to be "flouting the law" and endangering consumers. The focus on derivatives like 7-OH and MGM-15, which are considered "powerful psychoactive compounds," indicates a heightened regulatory sensitivity to modified or concentrated kratom products.

Compliance Implications for High-Risk Merchants: This lawsuit reinforces several critical compliance imperatives for businesses operating in the kratom space, particularly those categorized as high-risk:

1. Robust Lab Testing and COAs: Merchants must prioritize comprehensive, third-party lab testing for all products. Certificates of Analysis (COAs) should clearly detail the full alkaloid profile, including levels of mitragynine and 7-OH, and confirm the absence of contaminants. The lawsuit explicitly cites EDP Kratom's lack of "safety testing." Accurate and accessible COAs are not just good practice, but a vital defense against allegations of undisclosed ingredients or unsafe products.
2. Strict Regulatory Adherence: Compliance with all applicable state and federal regulations is paramount. This includes adhering to consumer protection laws like the Missouri Merchandising Practices Act, which prohibits deceptive trade practices. Merchants should be acutely aware of the Federal Food, Drug, and Cosmetic (FD&C) Act, especially concerning unapproved substances like 7-OH.
3. Transparent Labeling and Marketing: All product labeling and marketing materials must be truthful, accurate, and avoid misleading claims about safety, efficacy, or addiction potential. Downplaying risks or making unsubstantiated health claims can lead to severe legal repercussions. The practice of marketing products as "natural supplements" while containing synthesized or highly concentrated opioid-like derivatives is under intense scrutiny.
4. Ethical Business Practices: Targeting vulnerable populations or engaging in practices that could exacerbate addiction is a major liability. The allegations against EDP Kratom regarding shipping free 7-OH products to known addicts highlight the importance of ethical conduct and responsible sales practices.

As regulatory pressure on the kratom industry intensifies, proactive and rigorous compliance measures are no longer optional but essential for the long-term viability and integrity of any kratom business.